Safety assessment of a solid lipid curcumin particle preparation: Acute and subchronic toxicity studies

被引:60
作者
Dadhaniya, Paresh [2 ]
Patel, Chintan [2 ]
Muchhara, Jayesh [2 ]
Bhadja, Nilesh [2 ]
Mathuria, Neeta [2 ]
Vachhani, Kapil [2 ]
Soni, Madhu G. [1 ]
机构
[1] Soni & Associates Inc, Vero Beach, FL 32960 USA
[2] Cadila Pharmaceut Ltd, Preclin Dept, Dholka 387810, India
关键词
Curcumin; Food ingredient; Safety; Toxicity; Turmeric; PHARMACOKINETICS; VOLUNTEERS; CANCER; TRIAL; LONGA;
D O I
10.1016/j.fct.2011.05.001
中图分类号
TS2 [食品工业];
学科分类号
100403 [营养与食品卫生学];
摘要
Curcumin, a polyphenol, is obtained from turmeric, the ground rhizomes of Curcuma longa L Extensive research over the past half century has revealed several health benefits of curcumin. The objective of the present study was to investigate potential adverse effects, if any, of a novel solid lipid curcumin particle (SLCP) preparation in rats following acute and subchronic administration. The oral LD50 of the preparation in rats as well as in mice was found to be greater than 2000 mg/kg body weight (bw). In the subchronic toxicity study, Wistar rats (10/sex/group) were administered via oral gavage 0 (control), 180, 360, and 720 mg/kg bw/day of SLCP preparation for 90 days. Administration of the curcumin preparation did not result in any toxicologically significant treatment-related changes in clinical (including behavioral) observations, ophthalmic examinations, body weights, body weight gains, feed consumption, and organ weights. No adverse effects of the curcumin preparation were noted on the hematology, serum chemistry parameters, and urinalysis. Terminal necropsy did not reveal any treatment-related gross or histopathology findings. Based on the results of this study, the No Observed-Adverse-Effect Level (NOAEL) for this standardized novel curcumin preparation was determined as 720 mg/kg bw/day, the highest dose tested. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1834 / 1842
页数:9
相关论文
共 22 条
[1]
AGGARWAL B, 2007, TURMERIC GENUS CURCU, V1, P297
[2]
Aggarwal BB, 2003, ANTICANCER RES, V23, P363
[3]
Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets [J].
Aggarwal, Bharat B. ;
Sung, Bokyung .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (02) :85-94
[4]
PHARMACOLOGY OF CURCUMA-LONGA [J].
AMMON, HPT ;
WAHL, MA .
PLANTA MEDICA, 1991, 57 (01) :1-7
[5]
Chattopadhyay I, 2004, CURR SCI INDIA, V87, P44
[6]
Cheng AL, 2001, ANTICANCER RES, V21, P2895
[7]
Daybe F.V., 1870, Ber, V3, P609
[8]
Phase II trial of curcumin in patients with advanced pancreatic cancer [J].
Dhillon, Navneet ;
Aggarwal, Bharat B. ;
Newman, Robert A. ;
Wolff, Robert A. ;
Kunnumakkara, Ajaikumar B. ;
Abbruzzese, James L. ;
Ng, Chaan S. ;
Badmaev, Vladimir ;
Kurzrock, Razelle .
CLINICAL CANCER RESEARCH, 2008, 14 (14) :4491-4499
[9]
Curcumin as "Curecumin":: From kitchen to clinic [J].
Goel, Ajay ;
Kunnumakkara, Ajaikumar B. ;
Aggarwal, Bharat B. .
BIOCHEMICAL PHARMACOLOGY, 2008, 75 (04) :787-809
[10]
Safety and Pharmacokinetics of a Solid Lipid Curcumin Particle Formulation in Osteosarcoma Patients and Healthy Volunteers [J].
Gota, Vikram S. ;
Maru, Girish B. ;
Soni, Tejal G. ;
Gandhi, Tejal R. ;
Kochar, Nitin ;
Agarwal, Manish G. .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2010, 58 (04) :2095-2099